Pam Cheng
AstraZeneca
Executive VP of Global Operations & IT, Chief Sustainability Officer
Pam Cheng holds the position of Executive Vice President, Global Operations and Information Technology, and Chief Sustainability Officer for AstraZeneca. Guiding the company’s manufacturing, supply chain, procurement, IT and sustainability across 18 countries, she leads a team of over 20,000 employees. Under her leadership, AstraZeneca Global Operations has transformed significantly, driving top performance across the business while delivering value back to the enterprise. The next phase of transformation includes the convergence of operational excellence and digital innovation, building the ‘Factory of the Future’. In her role as Chief Sustainability Officer, she leads the company’s sustainability efforts to accelerate the delivery of net zero health systems.
Under Pam’s leadership and making the impossible possible, AstraZeneca Global Operations led the development, manufacturing, and supply of over 3 billion doses of COVID-19 vaccine to more than 170 countries. Two-thirds of which have been delivered to low/middle income countries. In parallel to this effort, she also led the development, manufacture and supply of over 3 million doses of AstraZeneca’s long-acting antibody, supporting the immunocompromised population against COVID-19.
Before joining AstraZeneca, she spent 18 years in global manufacturing, supply chain, and commercial roles at Merck/MSD. As President of MSD China, she was responsible for MSD’s entire business in China, including sales and marketing, commercial operations, and oversight of manufacturing and research and development. Prior to that, she was Head of Global Supply Chain Management and Logistics for Merck and led the transformation of Merck supply chains across the global supply network. Before joining the Biopharmaceutical industry, she held engineering and project management roles at UOP, Union Carbide Corporation, and GAF Chemicals.
In addition to her executive role at AstraZeneca, Pam is a Non-Executive Director for the Board at Smiths Group plc., a Trustee member of the Board at the Stevens Institute of Technology, and an Advisor to the Board of the International Society for Pharmaceutical Engineering (ISPE). Pam holds bachelor’s and master’s degrees in chemical engineering from Stevens Institute of Technology and an MBA in marketing from Pace University.
Under Pam’s leadership and making the impossible possible, AstraZeneca Global Operations led the development, manufacturing, and supply of over 3 billion doses of COVID-19 vaccine to more than 170 countries. Two-thirds of which have been delivered to low/middle income countries. In parallel to this effort, she also led the development, manufacture and supply of over 3 million doses of AstraZeneca’s long-acting antibody, supporting the immunocompromised population against COVID-19.
Before joining AstraZeneca, she spent 18 years in global manufacturing, supply chain, and commercial roles at Merck/MSD. As President of MSD China, she was responsible for MSD’s entire business in China, including sales and marketing, commercial operations, and oversight of manufacturing and research and development. Prior to that, she was Head of Global Supply Chain Management and Logistics for Merck and led the transformation of Merck supply chains across the global supply network. Before joining the Biopharmaceutical industry, she held engineering and project management roles at UOP, Union Carbide Corporation, and GAF Chemicals.
In addition to her executive role at AstraZeneca, Pam is a Non-Executive Director for the Board at Smiths Group plc., a Trustee member of the Board at the Stevens Institute of Technology, and an Advisor to the Board of the International Society for Pharmaceutical Engineering (ISPE). Pam holds bachelor’s and master’s degrees in chemical engineering from Stevens Institute of Technology and an MBA in marketing from Pace University.